A recent study indicates that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a major medical journal demonstrates that while obese people can lose about a fifth of their body weight while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"People buying such medications should be informed of the danger of quick rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to starting weight within about 18 months.
Comparing Therapies
The research, which looked at 37 of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
Researchers note that individuals who shed pounds through diet and exercise typically have a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Nutrition scientists believe the mode of action of the injections explains the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication means hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Issue?
The NHS advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts argue that, considering the likelihood of weight regain, the treatment is often long-term.
This view is echoed by pharmaceutical companies, who say that the findings "underscore the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
Users who have discontinued the medication describe a intense resurgence of appetite.
"It felt as if a switch flipping and I was suddenly starving," described a patient.
The struggle is exacerbated if patients have not developed lasting dietary or behavioural modifications during treatment.
Growing Interest
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while these medications are powerful tools for shedding pounds, they are not a standalone fix and lasting health benefits relies on combined behavioural support.
